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The activation, proliferation and survival of 
lymphocytes depend on the antigen receptor-induced 
formation of cytoplasmic signaling complexes that 
control specific transcriptional pathways. The protease 
MALT1 has an essential role in lymphocyte activation 
and lymphoma development [1, 2]. Upon antigen 
receptor triggering, MALT1 is recruited to the so-called 
CBM complex, formed by the assembly of the proteins 
CARMA1 (also known as CARD11), BCL-10 and 
MALT1. The CBM complex promotes the activation of the 
transcription factor NF-κB1 (also known as the classical 
NF-κB pathway) by two means: first, it allows MALT1 
to recruit and activate the IκB kinase (IKK)-complex, 
which phosphorylates and thereby inactivates the NF-
κB inhibitor IκB, and second, it promotes the MALT1-
dependent cleavage of proteins with negative regulatory 
roles in the NF-κB1 pathway, namely A20 and RelB 
(Figure 1A and 1B). MALT1 inhibitors already showed 
promise in preclinical lymphoma studies [3] and recent 
findings from our laboratory now suggest they may also be 
efficient against virally induced lymphomas [4]. 
Over the last few years, constitutive MALT1 
activation has been recognized as a common feature 
of various B cell malignancies and B cell proliferative 
diseases, such as diffuse large B-cell lymphoma of the 
activated B-cell subtype (ABC DLBCL), mantle cell 
lymphoma (MCL), MALT lymphoma and BENTA 
syndrome (Figure 1A and 1C) [2]. Recently, the proto-
oncogenic role of MALT1 has been extended to several T 
cell malignancies, such as adult T-cell leukemia/lymphoma 
(ATLL), peripheral T cell lymphoma (PTCL) and Sézary 
syndrome (Figure 1B) [2, 5]. The addiction of these 
lymphomas to MALT1’s protease and scaffold activity is 
mainly due to oncogenic somatic mutations that alter the 
activity or expression of components of the CBM complex 
itself or of its upstream signaling events, and/or to the 
recognition of self-antigens [2], as depicted in Figure 1 
(red stars indicate presence of mutations). A recurrent 
mutation found in MALT lymphoma is a chromosomal 
translocation that generates a MALT1-API2 fusion protein 
(Figure 1C). This fusion protein constitutively activates 
NF-κB1 through MALT1’s scaffold function and cleavage 
of classical MALT1 substrates. The API2 moiety of the 
MALT1-API2 fusion protein additionally recruits the 
kinase NIK and the tumor suppressor LIMA-1, whose 
cleavage promotes activation of the NF-κB2 pathway and 
cell growth, respectively [1, 2].
Lymphoid tumors can also be triggered by 
oncogenic herpes viruses, such as Epstein-Barr virus 
(EBV, also known as HHV-4), associated with Hodgkin 
and Burkitt lymphomas, or Kaposi’s sarcoma herpes 
virus (KSHV, also known as HHV-8), which induces 
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Figure 1: Constitutive MALT1 activation in lymphomas and lymphoproliferative disease
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primary effusion lymphoma (PEL) and multicentric 
Castleman disease-associated plasmablastic lymphomas 
[6]. Recently, we have proposed a possible role for 
MALT1 in the development of PEL (Figure 1D) [4]. 
PEL is a rare and incurable B-cell malignancy observed 
in immunocompromised patients. Malignant growth 
of KSHV-infected B cells requires the maintenance of 
viral latency and suppression of the viral lytic program. 
Amongst the KSHV latent genes, K13 and K15 are 
key regulators of NF-κB signaling [6]. K13 encodes 
a cytoplasmic protein of the FLIP family involved in 
inhibition of apoptosis and activation of NF-κB, while 
K15 encodes a membrane protein homologous to LMP2A 
(latent membrane protein 2A), an NF-κB inducing gene 
essential for EBV latency. K13 activates NF-κB1 through 
a physical interaction with NEMO/IKKγ that promotes the 
activation of the IKK complex (Figure 1D) [6]. K15, on 
the other hand, recruits and activates the Ser/Thr kinase 
NIK together with IKKα and β to activate NF-κB1. This 
requires an intact SH2-binding motif (Y481EEVL) in the 
cytoplasmic domain of K15 (Figure 1D) [6].
A recent study from our group has provided 
further insight into how K13 and K15 promote NF-κB1 
activation and viral latency, and identified the protease 
MALT1 as a key regulator of KSHV latency and growth 
of PEL [4]. We found that treatment with Thioridazine, 
an allosteric MALT1 inhibitor [7], strongly affected cell 
viability of several PEL cell lines in vitro [4]. Additionally, 
MALT1 inhibitors led to a dramatic reduction in PEL 
development in vivo using a xenograft model. Amongst 
the 86 open reading frames (ORFs) of KSHV, we 
identified K13 and K15 as potent MALT1 activators 
[4]. K13 directly interacted with the protease domain of 
MALT1 and may thus induce an active (or activatable) 
MALT1 conformation. K15 most likely activated MALT1 
indirectly, via the recruitment of (an) SH2-containing 
protein(s) to its cytoplasmic tail. Interestingly, the PEL 
cell lines used for this study lacked significant surface 
BCR expression and did not express the BCR signaling 
components BTK and CARMA1 [4]. PEL cells may thus 
use a KBM complex composed of K13, BCL-10 and 
MALT1, to activate MALT1 in a CARMA1-independent 
manner (Figure 1D). K15 might also contribute to KBM 
activation, and/or promote MALT1 activation through 
recruitment of unknown MALT1 activators [4].
In contrast to other lymphoid malignancies, where 
somatic mutations in cellular proteins activate MALT1 
in a constitutive manner, KSHV thus promotes MALT1 
activation by specific viral proteins that short-cut the 
requirement for CBM assembly. KSHV thereby exploits 
MALT1-dependent signal transduction to maintain its 
latency and escape the immune system. Consequently, 
MALT1 inhibition might be considered as an option to 
treat PEL patients, ideally in combination with an anti-
herpes virus drug that prevents viral replication and 
spreading, such as ganciclovir. Of note, MALT1 may also 
play a role in the latency maintenance of other viruses. 
Indeed, inhibition of MALT1 induced massive cell 
death in latently HIV-infected T cells under conditions 
of concurrent cellular activation [8]. Inhibiting MALT1 
activity might thus provide a more general therapeutic 
option to purge viruses such as KSHV and HIV from their 
latent reservoir.
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